Equities Analysts Set Expectations for Femasys Q3 Earnings

Femasys Inc. (NASDAQ:FEMY) – Research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Femasys in a report issued on Monday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.14). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Femasys’ FY2025 earnings at ($0.59) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at ($0.13) EPS.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. Femasys had a negative return on equity of 713.74% and a negative net margin of 1,113.72%. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.80 million.

Separately, Jones Trading decreased their price target on Femasys from $10.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, May 13th.

Femasys Trading Down 3.1%

Shares of NASDAQ:FEMY opened at $0.74 on Thursday. Femasys has a 12-month low of $0.69 and a 12-month high of $1.80. The company has a market capitalization of $24.19 million, a PE ratio of -0.86 and a beta of -2.58. The business has a 50 day moving average of $0.89 and a two-hundred day moving average of $1.13. The company has a current ratio of 0.89, a quick ratio of 0.54 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Femasys during the 2nd quarter worth approximately $82,000. Clear Creek Financial Management LLC boosted its holdings in Femasys by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 281,821 shares of the company’s stock worth $272,000 after buying an additional 11,450 shares during the last quarter. Dauntless Investment Group LLC acquired a new stake in Femasys in the 1st quarter worth about $1,969,000. Citadel Advisors LLC acquired a new stake in Femasys in the 4th quarter worth about $45,000. Finally, Northern Trust Corp boosted its holdings in Femasys by 42.6% in the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after buying an additional 37,675 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.